Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Recent evidence suggests psychedelics may significantly improve addiction treatment outcomes.
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
Psychedelics disrupt the brain networks responsible for the feeling of selfhood.
Real-time gathering of physiological data and subjective effects give clues that may help define a microdose of psilocybin.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.